What Is Aso In Healthcare?

What Is Aso In Healthcare
Administrative Services Only (ASO) Insurance – The Benefits Group Administrative services only (ASO) is an arrangement in which a company funds its own employee benefit plan, such as a health insurance program while purchasing only administrative services from the insurer.

What does ASO stand for?

How Common Are Administrative Services Only Plans? – Administrative services only plans continue to increase in popularity. They have long been favored by large companies that can spread the risk of expensive claims over a large number of employees and dependents.

What is the benefit of ASO?

An ASO plan, or ‘administrative services only,’ is a benefit plan in which the employer funds the benefits for employees rather than an insurance company. For example, a business can choose to pay for its employees’ health care rather than using an external insurance company to cover the costs.

What does ASO stand for contract?

What is an Administrative Services Only Agreement (ASO Agreement)? An administrative services only (ASO) agreement is a scheme in which an organization pays another organization to perform administrative functions related to insurance or benefits. By only outsourcing the administrative functions, organizations can handle claims themselves and avoid paying insurance premiums.

Insurance companies might still be involved in ASO agreements. However, unlike a traditional employee benefit plan, the insurance company only handles administrative services such as processing claims, but will not make any of the benefit payments. Companies that use these schemes save in premium costs, but they assume more risks.

It adds a certain amount of unpredictability to benefit programs because the employer has no way of knowing ahead of time how much they will have to pay out in claims. Share this Term : What is an Administrative Services Only Agreement (ASO Agreement)?

Is ASO the same as TPA?

Both can provide support for self-funded health plans. However, each serves a specific need. These two structures share some similarities but also differ in important ways:


TPA vs ASO	TPA	ASO
Autonomy	A TPA may operate independent of insurance companies.	An ASO is typically a subsidiary of a health insurance company.
Networks	A TPA often offers several PPO networks to choose from.	An ASO is typically limited to provider networks from the parent insurer.
Service	A TPA can assist in a wide range of areas, including enhanced reporting.	An ASO typically has limited services it can provide.

Outside of that notable difference, TPAs and ASOs both provide services for your self-funded healthcare plan. For example, both may allow outsourcing of insurance claims processing and record keeping. By partnering with a TPA, companies can often gain more coverage options as well as funding and reimbursement options.

What does ASO stand for in HR?

What is an ASO? – The term “ASO,” on the other hand, stands for Administrative Services Organization. The most important difference between an ASO and a PEO is that the service provided through an ASO does not establish a co-employer relationship. For example, an ASO does not process payroll and remit and report payroll taxes under its own FEIN, nor can it be the sponsor of any health and welfare benefits offered to its customers’ employees.

How does ASO work?

App Store Optimization (ASO) is a tactic that improves an app’s visibility in an app store. App stores rank each app based on a variety of factors. By successfully using optimal keywords, useful images and localized descriptions, you can rank higher and drive more downloads due to that visibility.

ASO is often compared to SEO, but the former only applies to an app store’s search function and ranking algorithms.
That being said, there are several ways SEO and ASO overlap – which may help you when first looking into improving App store rankings.
ASO is effectively a closed-site search engine.
Just like SEO, it relies on the right indexation, discoverable content and manipulation of the App store’s ranking algorithms.

If you can successfully communicate the uses of your app, both to the store and potential users, there’s huge potential to increase reach and drive installs, App Store Optimization helps you connect with a relevant audience and push your app’s unique selling points.

Why do hospitals have ASO?

REFERENCE: – 1. Jatene AD, Fontes VF, Paulista PP, Souza LC, Neger F, Galantier M, Sousa JE. Anatomic correction of transposition of the great vessels, J Thorac Cardiovasc Surg,1976; 72 :364–370.2. O’Brien SM, Clarke DR, Jacobs JP, Jacobs ML, Lacour-Gayet FG, Pizarro C, Welke KF, Maruszewski B, Tobota Z, Miller WJ, Hamilton L, Peterson ED, Mavroudis C, Edwards FH.

An empirically based tool for analyzing mortality associated with congenital heart surgery, J Thorac Cardiovasc Surg,2009; 138 :1139–1153.3. Sarris GE, Chatzis AC, Giannopoulos NM, Kirvassilis G, Berggren H, Hazekamp M, Carrel T, Comas JV, Di Carlo D, Daenen W, Ebels T, Fragata J, Hraska V, Ilyin V, Lindberg HL, Métras D, Pozzi M, Rubay J, Sairanen H, Stellin G, Urban A, van Doorn C, Ziemer G, European Congenital Heart Surgeons Association.

The arterial switch operation in Europe for transposition of the great arteries: a multi-institutional study from the European Congenital Heart Surgeons Association, J Thorac Cardiovasc Surg,2006; 132 :633–639.4. Fricke TA, Bulstra AE, Naimo PS, Bullock A, Robertson T, d’Udekem Y, Brizard CP, Konstantinov IE.

Excellent Long-Term Outcomes of the Arterial Switch Operation in Patients With Intramural Coronary Arteries, Ann Thoracic Surg,2016; 101 :725–729.5. Lara DA, Fixler DE, Ethen MK, Canfield MA, Nembhard WN, Morris SA. Prenatal diagnosis, hospital characteristics, and mortality in transposition of the great arteries,

Birth Def Res A Clin Mol Teratol,2016; 106 :739–748.6. Prandstetter C, Hofer A, Lechner E, Mair R, Sames-Dolzer E, Tulzer G. Early and mid-term outcome of the arterial switch operation in 114 consecutive patients, Clin Res Cardiol,2007; 96 :723–729.7.

Fricke TA, Bulstra AE, Loyer BR, Weintraub RG, d’Udekem Y, Brizard CP, Konstantinov IE. Outcomes of the Arterial Switch Operation in Children Less Than 2.5 Kilograms, Ann Thoracic Surg,2017; 103 :840–844.8. Mayer JE, Sanders SP, Jonas RA, Castañeda AR, Wernovsky G. Coronary artery pattern and outcome of arterial switch operation for transposition of the great arteries,

Circulation,1990; 82 :IV139–145.9. Wernovsky G, Mayer JE, Jonas RA, Hanley FL, Blackstone EH, Kirklin JW, Castañeda AR. Factors influencing early and late outcome of the arterial switch operation for transposition of the great arteries, J Thorac Cardiovasc Surg,1995; 109 :289–301– discussion 301–302.10.

Pasquali SK, Hasselblad V, Li JS, Kong DF, Sanders SP.
Coronary Artery Pattern and Outcome of Arterial Switch Operation for Transposition of the Great Arteries: A Meta-Analysis,
Circulation,2002; 106 :2575–2580.11.
Metton O, Calvaruso D, Gaudin R, Mussa S, Raisky O, Bonnet D, Sidi D, Vouhé PR.
Intramural coronary arteries and outcome of neonatal arterial switch operation,

Euro J Card Thorac Surg,2010; 37 :1246–1253.12. Brown JW, Park HJ, Turrentine MW. Arterial switch operation: factors impacting survival in the current era, Ann Thorac Surg,2001; 71 :1978–1984.13. Moll M, Michalak KW, Sobczak-Budlewska K, Moll JA, Kopala M, Szymczyk K, Dryżek P, Moll JJ.

Coronary Artery Anomalies in Patients With Transposition of the Great Arteries and Their Impact on Postoperative Outcomes,
Ann Thoracic Surg,2017; 104 :1620–1628.14.
Aramlou T, Jacobs ML, Pasquali S, He X, Hill K, O’Brien S, McMullan DM, Jacobs JP.
Surgeon and Center Volume Influence on Outcomes After Arterial Switch Operation: Analysis of the STS Congenital Heart Surgery Database,

Ann Thoracic Surg,2014; 98 :904–911.15. O’Byrne ML, Glatz AC, Shinohara RT, Jayaram N, Gillespie MJ, Dori Y, Rome JJ, Kawut S. Effect of center catheterization volume on risk of catastrophic adverse event after cardiac catheterization in children, Am Heart J,2015; 169 :823–832.e5.16.

O’Byrne ML, Glatz AC, Mercer-Rosa L, Gillespie MJ, Dori Y, Goldmuntz E, Kawut S, Rome JJ.
Trends in pulmonary valve replacement in children and adults with tetralogy of Fallot,
Am J Cardiol,2015; 115 :118–124.17.
O’Byrne ML, Gillespie MJ, Shinohara RT, Dori Y, Rome JJ, Glatz AC.
Cost comparison of Transcatheter and Operative Pulmonary Valve Replacement (from the Pediatric Health Information Systems Database),

Am J Cardiol,2016; 117 :121–126.18. O’Byrne ML, Glatz AC, Hanna BD, Shinohara RT, Gillespie MJ, Dori Y, Rome JJ, Kawut SM. Predictors of Catastrophic Adverse Outcomes in Children With Pulmonary Hypertension Undergoing Cardiac Catheterization: A Multi-Institutional Analysis From the Pediatric Health Information Systems Database,

J Am Coll Cardiol,2015; 66 :1261–1269.19.
Feudtner C, Hays RM, Haynes G, Geyer JR, Neff JM.
Deaths attributed to pediatric complex chronic conditions: national trends and implications for supportive care services,
Pediatr,2001; 107 :1–5.20.
O’Byrne ML, Gillespie MJ, Shinohara RT, Dori Y, Rome JJ, Glatz AC.

Cost comparison of transcatheter and operative closures of ostium secundum atrial septal defects, Am Heart J,2015; 169 :727–735.e2.21. O’Byrne ML, Shinohara RT, Grant EK, Kanter JP, Gillespie MJ, Dori Y, Rome JJ, Glatz AC. Increasing propensity to pursue operative closure of atrial septal defects following changes in the instructions for use of the Amplatzer Septal Occluder device: An observational study using data from the Pediatric Health Information Systems database,

Am Heart J,2017; 192 :85–97.22. Manning WG, Basu A, Mullahy J. Generalized modeling approaches to risk adjustment of skewed outcomes data, J Health Econ,2005; 24 :465–488.23. Sun G-W, Shook TL, Kay GL. Inappropriate use of bivariable analysis to screen risk factors for use in multivariable analysis, Journal of Clinical Epidemiology,1996; 49 :907–916.24.

Cepeda MS, Boston R, Farrar JT, Strom BL. Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders, AmJEpidemiol,2003; 158 :280–287.25. Jacobs ML, O’Brien SM, Jacobs JP, Mavroudis C, Lacour-Gayet F, Pasquali SK, Welke K, Pizarro C, Tsai F, Clarke DR.

An empirically based tool for analyzing morbidity associated with operations for congenital heart disease, J Thorac Cardiovasc Surg,2013; 145 :1046–1057.e1.26. Schidlow DN, Jenkins KJ, Gauvreau K, Croti UA, Giang DTC, Konda RK, Novick WM, Sandoval NF, Castañeda A. Transposition of the Great Arteries in the Developing World Surgery and Outcomes,

J Am Coll Cardiol,2017; 69 :43–51.27. Fricke TA, d’Udekem Y, Richardson M, Thuys C, Dronavalli M, Ramsay JM, Wheaton G, Grigg LE, Brizard CP, Konstantinov IE. Outcomes of the Arterial Switch Operation for Transposition of the Great Arteries: 25 Years of Experience,

Ann Thoracic Surg,2012; 94 :139–145.28. Chan PS, Oetgen WJ, Buchanan D, Mitchell K, Fiocchi FF, Tang F, Jones PG, Breeding T, Thrutchley D, Rumsfeld JS, Spertus JA. Cardiac performance measure compliance in outpatients: the American College of Cardiology and National Cardiovascular Data Registry’s PINNACLE (Practice Innovation And Clinical Excellence) program,

J Am Coll Cardiol,2010; 56 :8–14.29. Chan PS, Maddox TM, Tang F, Spinler S, Spertus JA. Practice-level variation in warfarin use among outpatients with atrial fibrillation (from the NCDR PINNACLE program), Am J Cardiol,2011; 108 :1136–1140.30. Hira RS, Kennedy K, Jneid H, Alam M, Basra SS, Petersen LA, Ballantyne CM, Nambi V, Chan PS, Virani SS.

Frequency and practice-level variation in inappropriate and nonrecommended prasugrel prescribing: insights from the NCDR PINNACLE registry,
J Am Coll Cardiol,2014; 63 :2876–2877.31.
Maddox TM, Chan PS, Spertus JA, Tang F, Jones P, Ho PM, Bradley SM, Tsai TT, Bhatt DL, Peterson PN.
Variations in coronary artery disease secondary prevention prescriptions among outpatient cardiology practices: insights from the NCDR (National Cardiovascular Data Registry),

J Am Coll Cardiol,2014; 63 :539–546.32. Hira RS, Kennedy K, Nambi V, Jneid H, Alam M, Basra SS, Ho PM, Deswal A, Ballantyne CM, Petersen LA, Virani SS. Frequency and practice-level variation in inappropriate aspirin use for the primary prevention of cardiovascular disease: insights from the National Cardiovascular Disease Registry’s Practice Innovation and Clinical Excellence registry,

J Am Coll Cardiol,2015; 65 :111–121.33.
Harahsheh AS, O’Byrne ML, Pastor B, Graham DA, Fulton DR.
Pediatric Chest Pain—Low-Probability Referral,
Clin Pediatr,2017; 56 :1201–1208.34.
Friedman KG, Rathod RH, Farias M, Graham D, Powell AJ, Fulton DR, Newburger JW, Colan SD, Jenkins KJ, Lock JE.
Resource utilization after introduction of a standardized clinical assessment and management plan,

Cong Heart Dis,2010; 5 :374–381.35. Fonarow GC, Yancy CW, Heywood JT, ADHERE Scientific Advisory Committee, Study Group, and Investigators. Adherence to heart failure quality-of-care indicators in US hospitals: analysis of the ADHERE Registry, Arch Intern Med,2005; 165 :1469–1477.36.

Arnold SV, Spertus JA, Masoudi FA, Daugherty SL, Maddox TM, Li Y, Dodson JA, Chan PS. Beyond medication prescription as performance measures: optimal secondary prevention medication dosing after acute myocardial infarction, J Am Coll Cardiol,2013; 62 :1791–1801.37. Peterson PN, Chan PS, Spertus JA, Tang F, Jones PG, Ezekowitz JA, Allen LA, Masoudi FA, Maddox TM.

Practice-level variation in use of recommended medications among outpatients with heart failure: Insights from the NCDR PINNACLE program, Circ Heart Fail,2013; 6 :1132–1138.38. Komajda M, Lapuerta P, Hermans N, Gonzalez-Juanatey JR, van Veldhuisen DJ, Erdmann E, Tavazzi L, Poole-Wilson P, Le Pen C.

Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey,
Eur Heart J,2005; 26 :1653–1659.39.
Irklin JW, Blackstone EH, Tchervenkov CI, Castañeda AR.
Clinical outcomes after the arterial switch operation for transposition.
Patient, support, procedural, and institutional risk factors.

Congenital Heart Surgeons Society, Circulation,1992; 86 :1501–1515.40. Anderson BR, Ciarleglio AJ, Hayes DA, Quaegebeur JM, Vincent JA, Bacha EA. Earlier arterial switch operation improves outcomes and reduces costs for neonates with transposition of the great arteries,

J Am Coll Cardiol,2014; 63 :481–487.41.
Cain MT, Cao Y, Ghanayem NS, Simpson PM, Trapp K, Mitchell ME, Tweddell JS, Woods RK.
Transposition of the great arteries-outcomes and time interval of early neonatal repair,
World J Pediatr Cong Heart Surg,2014; 5 :241–247.42.
Nevvazhay T, Chernogrivov A, Biryukov E, Biktasheva L, Karchevskaya K, Sulejmanov S, Kalinicheva J, Artemiev N.

Arterial switch in the first hours of life: no need for Rashkind septostomy? Eur J Cardiothorac Surg,2012; 42 :520–523.43. Chasovskyi K, Fedevych O, Vorobiova G, Zhovnir V, Maksimenko A, Boychenko O, Lysak Y, Cohen G, Yemets I. Arterial switch operation in the first hours of life using autologous umbilical cord blood,

Ann Thoracic Surg,2012; 93 :1571–1576.44.
Chasovskyi K, Mykychak Y, Rudenko N, Vorobyova H, Yemets I.
Five-year Experience With Arterial Switch Operation in the First Hours of Life,
Sem Thorac Cardiovasc Surg,2017; 29 :70–76.45.
McQuillen PS, Hamrick SEG, Perez MJ, Barkovich AJ, Glidden DV, Karl TR, Teitel D, Miller SP.

Balloon atrial septostomy is associated with preoperative stroke in neonates with transposition of the great arteries, Circulation,2006; 113 :280–285.46. Petit CJ, Rome JJ, Wernovsky G, Mason SE, Shera DM, Nicolson SC, Montenegro LM, Tabbutt S, Zimmerman RA, Licht DJ.

Preoperative brain injury in transposition of the great arteries is associated with oxygenation and time to surgery, not balloon atrial septostomy, Circulation,2009; 119 :709–716.47. Butts RJ, Ellis AR, Bradley SM, Hulsey TC, Atz AM. Effect of prostaglandin duration on outcomes in transposition of the great arteries with intact ventricular septum,

Congenit Heart Dis,2012; 7 :387–391.48. Bartlett JM, Wypij D, Bellinger DC, Rappaport LA, Heffner LJ, Jonas RA, Newburger JW. Effect of prenatal diagnosis on outcomes in D-transposition of the great arteries, Pediatr,2004; 113 :e335–e340.49. Blyth M, Howe D, Gnanapragasam J, Wellesley D.

The hidden mortality of transposition of the great arteries and survival advantage provided by prenatal diagnosis,
Brit J Obstet Gynecol,2008; 115 :1096–1100.50.
Bonnet D, Coltri A, Butera G, Fermont L, Le Bidois J, Kachaner J, Sidi D.
Detection of transposition of the great arteries in fetuses reduces neonatal morbidity and mortality,

Circulation,1999; 99 :916–918.

What are the different types of ASO?

Summary – ASO plans are a type of health insurance. Here, the organization contracts with an insurance company to provide administrative services. But the organization assumes some of the financial risks for paying claims. ASO plans have both advantages and disadvantages, so it’s important to understand both before deciding if an ASO plan is right for you.

If you’re considering an ASO plan for your organization, talk to your insurance broker or agent.
They can help you evaluate your options and find a plan that meets your needs.
What is administrative services only contract? An ASO contract is an agreement between an organization and an insurance company.

Here, the insurance company provides administrative services. But the organization assumes some of the financial risks for paying claims. ASO contracts serve a variety of insurance products, including health, dental, and life insurance. What is the difference between ASO and ASC? There is no difference between ASO and ASC.

They are both types of contracts in which the organization assumes some of the financial risks for paying claims. What is the difference between PEO and ASO? PEOs typically provide a comprehensive suite of HR services. ASO contracts are specifically for insurance services. What is the difference between a TPA and an ASO? A TPA is a third-party administrator that provides administrative services for an insurance plan.

With an ASO, the organization contracts with an insurance company. Here, they provide administrative services. But the organization assumes some of the financial risks for paying claims. What is the difference between an HMO and an ASO? An HMO is a plan that requires you to use a networked health insurance program.

How much does Aso make?

Work From Home ASO Specialist Salary

	Annual Salary	Monthly Pay
Top Earners	$100,000	$8,333
75th Percentile	$75,500	$6,291
Average	$59,710	$4,975
25th Percentile	$34,500	$2,875

What is an ASO professional?

PEO Vs. ASO Managing your business processes is a complicated task. You run the risk of costly penalties for noncompliance with federal and state employment law. Hiring human resources staff and developing the knowledge and expertise required to manage your business processes on a day-to-day basis can be time-consuming, difficult, and expensive, and keeps you from focusing on what you do best — running and growing your business.

Human resources (HR) is the cornerstone of your growing business. When considering an outside resource for HR, there are two common outsourcing options that companies consider: a PEO or an ASO. What is a PEO? A Professional Employer Organization (PEO) is a firm that partners with employers in a contractual co-employment relationship that involves shared responsibility for managing employees.

A PEO becomes the “employer of record” for your employees, in essence, terminating your employees, rehiring them as employees of the PEO, and moving them over to the PEO’s federal employer identification number (FEIN). Since the PEO is now the employer, the service provider chooses the benefits for you, provides you with the employee handbook and policies it requires you to use, and can often make decisions on how you hire and terminate employees.

Many companies feel this model of outsourced HR services removes much of their control over decisions regarding employees and even the business itself. They find this loss of control can be frustrating when, for example, they are told what benefits to offer and whether to hire or fire an employee. What is an ASO? An Administrative Services Organization (ASO) is a firm that provides similar services offered by PEOs, but does not “own” your employees.

The most important difference between an ASO and a PEO is that an ASO does not establish a co-employment relationship with your employees. Under an ASO agreement, your employees remain solely under your control. The ASO will handle your company’s payroll and tax filings, but the paperwork is filed under your company’s FEIN number.

Much like a PEO, an ASO oversees the day-to-day administrative aspects of managing your company’s human resource functions.
While an ASO does not sponsor employee benefit programs or workers’ compensation coverage (as a PEO does), it is generally active in arranging for and helping you secure coverage.

When working with an ASO, you can carve out your own benefit plans any way you want. Many companies prefer an ASO because it allows them to retain control without having to deal with mundane details on a daily basis. HR Knowledge: The Best of Both Models Our service delivery model is different.

We are not the employer of your employees, but we do provide virtually the same suite of services that a PEO offers — for a fraction of the cost.
We offer you the best of both service models without becoming the “employer of record.” HR Knowledge provides a toolbox full of resources and services to choose from in areas like benefits administration, employee onboarding, managed payroll, employee handbooks, employee training, and regulatory compliance.

We handle transactional HR tasks so that you can concentrate on company culture, employee retention, and productivity. We offer a single outsourcing solution that gives you more time to attend to strategic HR and to driving productivity and profitability in your organization.

Our cloud-based workforce management solutions integrate HR, time and attendance, and payroll functions to deliver better visibility and control of your labor costs, productivity, and compliance. While HR Knowledge is an ASO, we consider ourselves a Human Resources Outsourcing (HRO) service provider.

HRO is one of the fastest-growing segments of the Business Process Outsourcing (BPO) market. According to Forbes, an estimated 50 percent of large companies outsource all or some of their HR services. Small businesses are now following the lead of larger companies, having quickly recognized that HRO is a cost-effective alternative.

Many businesses are turning to HRO firms to help them manage payroll, benefits and HR administration, workplace compliance, and recruiting.
Businesses are always looking for ways to reduce costs and improve efficiencies and productivity.
By outsourcing certain HR functions, business leaders gain time to play a more strategic role in their organizations.

To learn more about the differences between a PEO and ASO, please contact us, and put HR Knowledge to work in your business so you can focus on your business. : PEO Vs. ASO

What title is ASO?

App Subtitle (Apple) & Short Description (Google) – Apple’s “app subtitle” and Google’s “short description” are not the same, but the goal is similar. For the sake of this article, let’s put them together. The goal of this section for your ASO Strategy is to tell all the people who land on your App Store Page what they will find in your app or game. What Is Aso In Healthcare In ASO (App Store Optimization) terms, App Subtitle & Short Description work somewhat similarly to the app title. They cause an impact on your app’s rankings and visibility, even though the algorithm does not consider them as important as the Title. The App Store Optimization challenge here is to use other core keywords for your app in subtitles or short descriptions in such a way as also to keep the style both appealing and informative.

What is an ASO and when would it be used?

Available Administrative Services In An ASO Plan – In an ASO arrangement, employers purchase specific administrative services from a third-party administration (TPA) to be carried out by the TPA. Typical services offered in an ASO situation can include:

Preparing administration manual. Managing COBRA, HRA, HSA, FSA, and the like. Communicating with employees. Managing benefits enrollment. Determining benefits. Evaluating claims. Processing claims. Paying benefits. Preparing government reports. Preparing summary plan descriptions. Conducting accounting matters.

Essentially a self-funded plan, an ASO arrangement is usually offered for short-term disability, extended health and dental care benefits, and sometimes long-term disability benefits. Employers rarely provide life insurance under an ASO system because of the large coverage amounts.

What does tPA stand for medical?

List of References –

Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, de Ferranti SD, Floyd J, Fornage M, Gillespie C, Isasi CR, Jiménez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Mackey RH, Matsushita K, Mozaffarian D, Mussolino ME, Nasir K, Neumar RW, Palaniappan L, Pandey DK, Thiagarajan RR, Reeves MJ, Ritchey M, Rodriguez CJ, Roth GA, Rosamond WD, Sasson C, Towfighi A, Tsao CW, Turner MB, Virani SS, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation.2017 Mar 7;135(10):e146-e603. PMID: 28122885 Ma J, Ward EM, Siegel RL, Jemal A. Temporal Trends in Mortality in the United States, 1969-2013. JAMA.2015 Oct 27;314(16):1731-9. PMID: 26505597 Reviewed in Barreto AD. Intravenous thrombolytics for ischemic stroke. Neurotherapeutics.2011 Jul;8(3):388-99. PMID: 21638138 (NIH and private support, including NINDS grants NB06833 and NB03564) Astrup T, Permin PM. Fibrinolysis in animal organism. Nature 1947;159:68 1–2. PMID: 2034226 (Denmark, source not given) Collen D, Billiau A, Edy J, De Somer P. Identification of the human plasma protein which inhibits fibrinolysis associated with malignant cells. Biochim Biophys Acta.1977 Sep 29;499(2):194-201. PMID: 198009 (Belgium, private support) Matsuo O, Rijken DC, Collen D. Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolus. Nature.1981 Jun 18;291(5816):590-1. PMID: 7195468 (Belgium, private support) Van de Werf F, Ludbrook PA, Bergmann SR, Tiefenbrunn AJ, Fox KA, de Geest H, Verstraete M, Collen D, Sobel BE. Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. N Engl J Med.1984 Mar 8;310(10):609-13. PMID: 6537987 (NIH/NHLBI grant HL17646, private support) Pennica D, Holmes WE, Kohr WJ, Harkins RN, Vehar GA, Ward CA, Bennett WF, Yelverton E, Seeburg PH, Heyneker HL, Goeddel DV, Collen D. Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature.1983 Jan 20;301(5897):214-21. PMID: 6337343 (Genentech) Collen D, Topol EJ, Tiefenbrunn AJ, Gold HK, Weisfeldt ML, Sobel BE, Leinbach RC, Brinker JA, Ludbrook PA, Yasuda I, et al. Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial. Circulation.1984 Dec;70(6):1012-7. PMID: 6388898 (Genentech) TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. N Engl J Med.1985 Apr 4;312(14):932-6. PMID: 4038784 (NIH/NHLBI contract; Genentech, tPA) Dalen JE, Gore JM, Braunwald E, Borer J, Goldberg RJ, Passamani ER, Forman S, Knatterud G. Six- and twelve-month follow-up of the phase I Thrombolysis in Myocardial Infarction (TIMI) trial. Am J Cardiol.1988 Aug 1;62(4):179-85. PMID: 3135737 (NIH/NHLBI contract; Genentech, tPA) U.S. Food and Drug Administration. Drugs@FDA: FDA Approved Drug Products. Available at: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm, Accessed May 4, 2017. Zivin JA, Fisher M, DeGirolami U, Hemenway CC, Stashak JA. Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science.1985 Dec 13;230(4731):1289-92. PMID: 3934754 (Private support; NINDS-supported investigator) Penar PL, Greer CA. The effect of intravenous tissue-type plasminogen activator in a rat model of embolic cerebral ischemia. Yale J Biol Med.1987 May-Jun;60(3):233-43. PMID: 3111108 (NIH/NINDS, grants NS10174, NS19430) Zivin JA, Lyden PD, DeGirolami U, Kochhar A, Mazzarella V, Hemenway CC, Johnston P. Tissue plasminogen activator. Reduction of neurologic damage after experimental embolic stroke. Arch Neurol.1988 Apr;45(4):387-91. PMID: 3128254 (NIH/NINDS, grants NS23323, NS23814; US Dept. of Veterans Affairs (VA); Genentech, tPA) Phillips DA, Fisher M, Smith TW, Davis MA. The safety and angiographic efficacy of tissue plasminogen activator in a cerebral embolization model. Ann Neurol.1988 Apr;23(4):391-4. PMID: 3132892 (Private support – Genentech and other private) Lyden PD, Zivin JA, Clark WA, Madden K, Sasse KC, Mazzarella VA, Terry RD, Press GA. Tissue plasminogen activator-mediated thrombolysis of cerebral emboli and its effect on hemorrhagic infarction in rabbits. Neurology.1989 May;39(5):703-8. PMID: 2496332 (NIH/NINDS, grant NS23814; VA; Burroughs Wellcome Co., tPA) Overgaard K, Sereghy T, Boysen G, Pedersen H, Diemer NH. Reduction of infarct volume and mortality by thrombolysis in a rat embolic stroke model. Stroke.1992 Aug;23(8):1167-73; discussion 1174. PMID: 1636193 (Denmark, private support) Ringelstein EB, Biniek R, Weiller C, Ammeling B, Nolte PN, Thron A. Type and extent of hemispheric brain infarctions and clinical outcome in early and delayed middle cerebral artery recanalization. Neurology.1992 Feb;42(2):289-98. PMID: 1736156 (Germany, source not given) von Kummer R, Hacke W. Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery stroke. Stroke.1992 May;23(5):646-52. PMID: 1579960 (Germany, source not given) Brott TG, Haley EC Jr, Levy DE, Barsan W, Broderick J, Sheppard GL, Spilker J, Kongable GL, Massey S, Reed R, et al. Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke.1992 May;23(5):632-40. PMID: 1579958 (NIH/NINDS, intramural and grants NS03342, NS32324, NS51007; Genentech, tPA) Haley EC Jr, Levy DE, Brott TG, Sheppard GL, Wong MC, Kongable GL, Torner JC, Marler JR. Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke.1992 May;23(5):641-5. PMID: 1579959 (NIH/NINDS, grant number not given) Mori E, Yoneda Y, Tabuchi M, Yoshida T, Ohkawa S, Ohsumi Y, Kitano K, Tsutsumi A, Yamadori A. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology.1992 May;42(5):976-82. PMID: 1579252 (Sumitomo Pharmaceuticals, Tokyo, Japan) Haley EC Jr, Brott TG, Sheppard GL, Barsan W, Broderick J, Marler JR, Kongable GL, Spilker J, Massey S, Hansen CA, et al. Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke. The TPA Bridging Study Group. Stroke.1993 Jul;24(7):1000-4. PMID: 8322373 (Genentech; NINDS intramural) National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med.1995 Dec 14;333(24):1581-7. PMID: 7477192, LINK (NIH/NINDS, contracts NS02382, NS02374, NS02377, NS02381, NS02379, NS02373, NS02378, NS02376, NS02380; Genentech, tPA) U.S. Food and Drug Administration. Drugs@FDA: FDA Approved Drug Products. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/1996/altegen061896L.htm, Accessed May 4, 2017. Kwiatkowski TG, Libman RB, Frankel M, Tilley BC, Morgenstern LB, Lu M, Broderick JP, Lewandowski CA, Marler JR, Levine SR, Brott T. Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. N Engl J Med.1999 Jun 10;340(23):1781-7. PMID: 10362821 Gladstone DJ, Black SE. Update on intravenous tissue plasminogen activator for acute stroke: from clinical trials to clinical practice. CMAJ.2001 Aug 7;165(3):311-7. Review. PMID: 11517650 (Private and unknown funding sources) Fagan SC, Morgenstern LB, Petitta A, Ward RE, Tilley BC, Marler JR, Levine SR, Broderick JP, Kwiatkowski TG, Frankel M, Brott TG, Walker MD. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group. Neurology.1998 Apr;50(4):883-90. PMID: 9566367 (NIH/NINDS contracts NS02382, NS02374, NS02377, NS02381, NS02379, NS02373, NS02376, NS02378, and NS02380) Know Stroke Home: About the Campaign. Available at: https://stroke.nih.gov/about/index.htm, Accessed April 3, 2017. Furlan AJ. Endovascular therapy for stroke-it’s about time. N Engl J Med.2015 Jun 11;372(24):2347-9. PMID: 25882509 U.S. Food and Drug Administration. FDA allows marketing of clot retrieval devices to reduce disability in stroke patients, September 2, 2016. Available at: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm519042.htm, Accessed April 3, 2017. Nogueira RG, Jadhav AP, Haussen DC, Bonafe A, Budzik RF, Bhuva P, Yavagal DR, Ribo M, Cognard C, Hanel RA, Sila CA, Hassan AE, Millan M, Levy EI, Mitchell P, Chen M, English JD, Shah QA, Silver FL, Pereira VM, Mehta BP, Baxter BW, Abraham MG, Cardona P, Veznedaroglu E, Hellinger FR, Feng L, Kirmani JF, Lopes DK, Jankowitz BT, Frankel MR, Costalat V, Vora NA, Yoo AJ, Malik AM, Furlan AJ, Rubiera M, Aghaebrahim A, Olivot JM, Tekle WG, Shields R, Graves T, Lewis RJ, Smith WS, Liebeskind DS, Saver JL, Jovin TG; DAWN Trial Investigators. Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct. N Engl J Med.2018 Jan 4;378(1):11-21. PMID: 29129157 (Private support – Stryker Neurovascular) Albers GW, Marks MP, Kemp S, Christensen S, Tsai JP, Ortega-Gutierrez S, McTaggart RA, Torbey MT, Kim-Tenser M, Leslie-Mazwi T, Sarraj A, Kasner SE, Ansari SA, Yeatts SD, Hamilton S, Mlynash M, Heit JJ, Zaharchuk G, Kim S, Carrozzella J, Palesch YY, Demchuk AM, Bammer R, Lavori PW, Broderick JP, Lansberg MG; DEFUSE 3 Investigators. Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging. N Engl J Med.2018 Jan 24. PMID: 29364767 (NIH/NINDS, grants NS086487 and NS092076)

What is the difference between self funded and fully insured?

Fully-insured plan—employer purchases insurance from an insurance company. Self-funded plan—employer provides health benefits directly to employees. insurance company assumes the risk of providing health coverage for insured events.

What kind of drug is tPA?

What is TPA? – TPA is a thrombolytic or a “Clot Buster” drug. This clot buster is used to break-up the clot that is causing a blockage or disruption in the flow of blood to the brain and helps restore the blood flow to the area of the brain. It is given by intravenous (IV), not by mouth.

What is an ASO manager?

A leading digital and social game publisher, Gameloft® has established itself as one of the top innovators in its field since 2000. Gameloft creates games for all digital platforms and with an audience of 157 million monthly users offers via Gameloft Advertising Solutions a unique level of visibility and involvement to advertisers.

Gameloft operates its own established franchises such as Asphalt®, Order & Chaos, Modern Combat and Dungeon Hunter and also partners with major rights holders including Universal, Illumination Entertainment, Disney®, Marvel®, Hasbro®, Fox Digital Entertainment, Mattel®, and Ferrari®.
Gameloft distributes its games in over 100 countries.

Gameloft is a Vivendi company. The company has operated in Ukraine since 2007. Gameloft Kharkiv is one of the largest and the most successful Gameloft Studios. Gameloft Lviv is a young Studio that continues to grow, establishing a full development pipeline for mobile games.

1−3 years’ experience in ASO;Previously planned & implemented App Store Optimization strategies for mobile games of different genres, achieving significant app user base growth;Good understanding of ASO, including knowledge of app store algorithms, optimization methods and effective strategies for improving app stores performance and growing app installs;Strong analytical skills, including the ability to analyze statistical data to make optimization decisions, providing data reports analysis and case studies;Experience with app store optimization and analytics tools and software (AppAnnie, SensorTower, StoreMaven, Mobile Action, AppsFlyer etc.);Experience with project management, comfortable multi-tasking in a fast-paced environment;Ability to manage multiple projects and to identify and prioritize the ones with highest impact at lowest opportunity cost;Very strong interpersonal skills, including building relationships and collaborating with internal teams in remote locations, and with external vendors;Fluent in English;2+ years in consumer marketing, ideally in online entertainment or social products;Knowledge and passion for video games from hardcore gamers titles to casual social games, and entertainment as a whole.

Organic visibility & Store conversion rate

Build the ASO yearly roadmap in accordance to new releases and objectives set up by the Game team;Implement the keyword optimization strategy for all the markets: from keyword research to keyword analysis;Work alongside with translation team to localize the keyword strategy, visual and written assets for all markets;Work alongside with MAS team to make sure visual and written assets comply with store’s guidelines and policies;Implement the A/B testing strategy from the beginning to end: build roadmap and hypothesis, create the assets, apply the tests and monitor closely impact on stores;Define and launch LiveOps cards in order to boost store performance and revenue;Apply for featurings and provide the deliverables requested by Partnership team on time each quarter;Take care of the submission of new visual and written assets on all the consoles OR verify that all the submissions files have been properly uploaded: build, visual and written assets, per localization;Work alongside with UA manager to challenge the ASA strategy (if there is any) and improve your understanding of UA impact on organic performance;Monitor average rating to make sure the game is always above 4* and, if needed, challenge the in-app prompt strategy;Expand your knowledge on third party platforms and PC platforms.

Reporting & Benchmark

Conduct regular competitor’s benchmark and stay abreast of the latest ASO trends;Analyze experiments results and create post-mortem/case-study to share learnings with other teams;Monitor and report App store performance and other ASO metrics for all the consoles (Crashes, CSR, etc.);Monitor and report all the featurings received on the stores, especially the ones pitched by Partnership team;Monitor and report all the LiveOps content promoted on the stores;Discuss and share best practices with other ASO experts through monthly calls and by updating the dedicated Confluence pages;Investigate and implement new hypothesis to find new ways to increase the organic visibility of your apps.

Benefits:

Join a leading global mobile and video games publisher and developer utilizing the state-of-art mobile technologies and devices;Become a part of the talented international team in a friendly, creative and dynamic environment;Become a true pro in the fast-growing, exciting and innovative video games industry;Be proud to deliver the prestigious products winning the top rankings worldwide;Build up your career with dynamic promotions and worldwide opportunities.

In order to consider your application, we require you to send the full version of your CV in English. Qualified candidates will be asked to complete a test assessment.

What is the role of ASO manager?

As a ASO/SEO Manager, you will be responsible for setting up, implementing, and managing the overall company’s ASO/SEO strategies and optimization.

What title is ASO?

What are the different types of ASO?

If you’re considering an ASO plan for your organization, talk to your insurance broker or agent. They can help you evaluate your options and find a plan that meets your needs. What is administrative services only contract? An ASO contract is an agreement between an organization and an insurance company.

They are both types of contracts in which the organization assumes some of the financial risks for paying claims.
What is the difference between PEO and ASO? PEOs typically provide a comprehensive suite of HR services.
ASO contracts are specifically for insurance services.
What is the difference between a TPA and an ASO? A TPA is a third-party administrator that provides administrative services for an insurance plan.